BRPI1007945A2 - Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente - Google Patents

Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente

Info

Publication number
BRPI1007945A2
BRPI1007945A2 BRPI1007945-9A BRPI1007945A BRPI1007945A2 BR PI1007945 A2 BRPI1007945 A2 BR PI1007945A2 BR PI1007945 A BRPI1007945 A BR PI1007945A BR PI1007945 A2 BRPI1007945 A2 BR PI1007945A2
Authority
BR
Brazil
Prior art keywords
patient
nitazoxanide
nitazoxinide
tizoxanide
bioavailability
Prior art date
Application number
BRPI1007945-9A
Other languages
English (en)
Inventor
Jean-François Rossignol
Marc Ayers
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of BRPI1007945A2 publication Critical patent/BRPI1007945A2/pt
Publication of BRPI1007945B1 publication Critical patent/BRPI1007945B1/pt
Publication of BRPI1007945B8 publication Critical patent/BRPI1007945B8/pt
Publication of BRPI1007945C1 publication Critical patent/BRPI1007945C1/pt
Publication of BRPI1007945C8 publication Critical patent/BRPI1007945C8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI1007945A 2009-02-13 2010-02-12 formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral BRPI1007945C8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20228509P 2009-02-13 2009-02-13
US61/202285 2009-02-13
PCT/US2010/024000 WO2010093854A1 (en) 2009-02-13 2010-02-12 Controlled release pharmaceutical formulations of nitazoxanide

Publications (5)

Publication Number Publication Date
BRPI1007945A2 true BRPI1007945A2 (pt) 2015-09-01
BRPI1007945B1 BRPI1007945B1 (pt) 2020-08-04
BRPI1007945B8 BRPI1007945B8 (pt) 2020-08-18
BRPI1007945C1 BRPI1007945C1 (pt) 2020-09-01
BRPI1007945C8 BRPI1007945C8 (pt) 2021-05-25

Family

ID=42560126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007945A BRPI1007945C8 (pt) 2009-02-13 2010-02-12 formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral

Country Status (23)

Country Link
US (5) US8524278B2 (pt)
EP (1) EP2395840B1 (pt)
JP (3) JP5726766B2 (pt)
KR (1) KR101697800B1 (pt)
CN (2) CN102395276A (pt)
AU (3) AU2010213678B2 (pt)
BR (1) BRPI1007945C8 (pt)
CA (1) CA2752233C (pt)
CO (1) CO6501159A2 (pt)
CY (1) CY1123162T1 (pt)
DK (1) DK2395840T3 (pt)
EA (1) EA029018B1 (pt)
ES (1) ES2797493T3 (pt)
HR (1) HRP20201055T1 (pt)
HU (1) HUE049501T2 (pt)
IL (1) IL214624A0 (pt)
LT (1) LT2395840T (pt)
MX (1) MX348282B (pt)
PL (1) PL2395840T3 (pt)
PT (1) PT2395840T (pt)
SI (1) SI2395840T1 (pt)
UA (1) UA107564C2 (pt)
WO (1) WO2010093854A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200806310B (en) * 2006-01-09 2009-12-30 Romark Lab Lc Viral hepatitis treatment
JP5726766B2 (ja) * 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル.シー. ニタゾキサニドの制御放出医薬配合物
BR112014018149B1 (pt) 2012-01-27 2020-09-29 Siegfried Rhein S.A. De C.V Composição farmacêutica de nitazoxanida
US20150017242A1 (en) * 2012-02-20 2015-01-15 Lupin Limited Bilayer Tablet of Dronedarone
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
PL3436074T3 (pl) 2016-03-31 2020-11-02 Romark Laboratories, L.C. Związki z grupą tiazolidynową do leczenia zakażeń wirusowych
MX2018012285A (es) * 2016-04-11 2019-02-07 Genfit Metodos de tratamiento para enfermedades colestasicas y fibroticas.
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
CN110381925A (zh) * 2017-03-08 2019-10-25 辛瑞克斯制药有限公司 间苯三酚和三甲基间苯三酚的药物制剂
US11191749B2 (en) * 2017-03-13 2021-12-07 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 mTORインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
CN110025621A (zh) * 2019-03-13 2019-07-19 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
CN114845704A (zh) * 2019-12-19 2022-08-02 赛特瑞恩股份有限公司 包含西苯唑啉或其盐的药物制剂
WO2022020243A1 (en) 2020-07-20 2022-01-27 Romark Laboratories L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
AU2021333566A1 (en) 2020-08-24 2023-03-16 Romark Laboratories L.C. Use of thiazolides against coronaviruses
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
AU740022B2 (en) * 1997-05-07 2001-10-25 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5948440A (en) 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
RU2236847C2 (ru) 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
RU2285519C2 (ru) 2000-09-29 2006-10-20 Солвей Фармасьютикалс Б.В. Фармацевтическая композиция с пролонгированным высвобождением, независимым от ионной силы
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
PL370818A1 (en) 2001-09-28 2005-05-30 Sun Pharmaceutical Industries Limited Dosage form for treatment of diabetes mellitus
JP2005509604A (ja) * 2001-09-28 2005-04-14 マクニール−ピーピーシー・インコーポレイテッド 菓子組成物を含む剤形
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
UY28457A1 (es) 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
ZA200806310B (en) * 2006-01-09 2009-12-30 Romark Lab Lc Viral hepatitis treatment
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
PT2178852E (pt) * 2007-08-03 2015-11-12 Romark Lab Lc Compostos tiazolida substituídos com alquilsulfonilo
JP5726766B2 (ja) * 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル.シー. ニタゾキサニドの制御放出医薬配合物

Also Published As

Publication number Publication date
UA107564C2 (uk) 2015-01-26
US20180085353A1 (en) 2018-03-29
SI2395840T1 (sl) 2020-08-31
JP2015143258A (ja) 2015-08-06
EA201190127A1 (ru) 2012-03-30
AU2016200971A1 (en) 2016-03-03
JP2012518002A (ja) 2012-08-09
US9351937B2 (en) 2016-05-31
EP2395840A1 (en) 2011-12-21
CO6501159A2 (es) 2012-08-15
EA029018B1 (ru) 2018-01-31
EP2395840A4 (en) 2013-12-25
AU2010213678B2 (en) 2015-11-26
US20160243087A1 (en) 2016-08-25
ES2797493T3 (es) 2020-12-02
BRPI1007945C8 (pt) 2021-05-25
BRPI1007945B1 (pt) 2020-08-04
HRP20201055T1 (hr) 2020-10-30
PL2395840T3 (pl) 2020-09-07
JP6491174B2 (ja) 2019-03-27
JP6117845B2 (ja) 2017-04-19
MX348282B (es) 2017-06-05
AU2017203148B2 (en) 2018-08-09
KR101697800B1 (ko) 2017-01-18
US20140065215A1 (en) 2014-03-06
CY1123162T1 (el) 2021-10-29
AU2010213678A1 (en) 2011-09-01
EP2395840B1 (en) 2020-04-15
JP2017061561A (ja) 2017-03-30
CA2752233C (en) 2017-01-03
CN107260695A (zh) 2017-10-20
WO2010093854A1 (en) 2010-08-19
PT2395840T (pt) 2020-07-06
BRPI1007945C1 (pt) 2020-09-01
US10383855B2 (en) 2019-08-20
AU2017203148A1 (en) 2017-06-01
US8524278B2 (en) 2013-09-03
CA2752233A1 (en) 2010-08-19
MX2011008530A (es) 2011-10-14
LT2395840T (lt) 2020-07-10
US20190321338A1 (en) 2019-10-24
AU2016200971B2 (en) 2017-02-23
KR20120008024A (ko) 2012-01-25
US9827227B2 (en) 2017-11-28
HUE049501T2 (hu) 2020-09-28
US20100209505A1 (en) 2010-08-19
US11426388B2 (en) 2022-08-30
BRPI1007945B8 (pt) 2020-08-18
DK2395840T3 (da) 2020-06-08
JP5726766B2 (ja) 2015-06-03
IL214624A0 (en) 2011-09-27
CN102395276A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI1007945A2 (pt) Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
AP2011005901A0 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2010009270A (es) Compuestos y metodos para la prevencion o tratamiento de reestenosis.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PL2308497T3 (pl) Kompozycja farmaceutyczna zawierająca glikozoaminoglikany oraz jej zastosowanie w leczeniu przewlekłych owrzodzeń
ZA201001117B (en) The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
BRPI0819195A2 (pt) métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
WO2011106378A3 (en) Oral b12 therapy
BRPI1006879A2 (pt) combinação, composição farmacêutica, uso de uma combinação, e, método de tratamento ou profilaxia de uma doença ou condição.
WO2010148533A8 (zh) 治疗糖尿病的医药组合物
WO2009045054A3 (en) A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO QUADRO REIVINDICATORIO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24D Patent annual fee: restoration after fee payment